RxDoctor Payments Data

Arpita Patel

Nurse Practitioner · Hoffman Estates, ILNPI 1932768025

Payments from drug & device makers

$4,026in general payments, 2019–2025

Across 125 payments — averaging $32.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$786
  • Teleflex LLC$752
  • Astellas Pharma US Inc$483
  • Sumitomo Pharma America, Inc.$356
  • Urogen Pharma, Inc.$220
  • Convatec Inc.$165
  • plus $1K from 23 others

What the payments were for

  • Travel & lodging$50413%
  • Food & beverage$3,22280%
  • Education$3007%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,026 in reported general payments places this provider in the 95th percentile of 4,869 nurse practitioner providers in Illinois.

See all nurse practitioner providers in Illinois

Medicare billing

Part B allowed, 2024
$72,989
Medicare patients
387
Services billed
1,297

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron59$47,570
MyrbetriqMirabegron42$44,919
Tamsulosin Hcl260$4,629
Methenamine Hippurate35$2,186
Trospium Chloride35$2,063
Estradiol24$1,520
Finasteride71$1,191
Testosterone14$1,183
Alfuzosin Hcl ErAlfuzosin Hcl21$482
Cefdinir24$364
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav35$243
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst16$158
Cephalexin29$137
Doxycycline Hyclate11$92
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim19$37

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$356$47,57059 claims
Astellas Pharma US IncMyrbetriq$483$44,91942 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,869 nurse practitioner providers in Illinois.

Other nurse practitioner in Hoffman Estates

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →